Calleris, Giorgio
Rouprêt, Morgan
Seisen, Thomas
Bendjeddou, Lyamin
Chevallier, Thierry
Masson-Lecomte, Alexandra
Thibault, Constance
Neuzillet, Yann
Audenet, François
Xylinas, Evanguelos
Houédé, Nadine
Clinical trials referenced in this document:
Documents that mention this clinical trial
Design and rationale of a single-arm phase II study of neoadjuvant Durvalumab and Gemcitabine associated with Cisplatin or Carboplatin for upper urinary tract urothelial cancer: the iNDUCT trial (NCT04617756)
https://doi.org/10.1007/s00345-023-04596-5
Article History
Received: 27 March 2023
Accepted: 23 August 2023
First Online: 12 September 2023
Declarations
:
: Morgan Rouprêt declares to be part of the advisory board for UroGen Pharma, Bristol-Myers Squibb, Janssen Pharmaceuticals, Astellas Pharma, Ipsen, and Cepheid; Constance Thibault for AAA, Astellas, AstraZeneca, Ipsen, Janssen, Pfizer, Merck, MSD, BMS, and Seagen; François Audenet for Astellas, Bristol-Myers Squibb, Ipsen, and Pfizer; Yann Neuzillet for Astellas, AstraZeneca, Bayer, BMS, Bouchara Recordati, Ferring, Ipsen, Janssen-Cilag, Merck, MSD, Novartis, and Pfizer; and Nadine Houédé for Astra Zeneca, Bayer, Bristol-Myers Squibb, Janssen Pharmaceuticals, and Ipsen. Giorgio Calleris, Lyamin Bendjeddou, Thomas Seisen, Thierry Chevallier, Alexandra Masson-Lecomte, and Evanguelos Xylinas have no competing interests to declare that are relevant to the content of this article.
: This article does not report any personal data and requires no patient consent for publication. All patients enrolled in this study whose protocol is here presented have subscribed a written informed consent in accordance with applicable regulation and ethical standards.
: The present article consists in a narrative review of the literature and in the presentation of a study protocol; therefore, it does not directly involve human participants. The study protocol presented in this article was approved by the appropriate institutional ethics committee, “Comité de Protection des Personnes”, and by the “Agence nationale de sécurité du médicament et des produits de santé”. The authors certify that the study whose protocol is here presented is being performed in accordance with the ethical standards as laid down in the 1964 Declaration of Helsinki and its later amendments or comparable ethical standards. Trial registration number is NCT04617756 and it is supervised by an independent data monitoring committee.